Guardian Wealth Advisors LLC Has $418,000 Stock Position in The Clorox Company (NYSE:CLX)

Guardian Wealth Advisors LLC decreased its stake in shares of The Clorox Company (NYSE:CLX) by 12.2% during the 1st quarter, Holdings Channel reports. The firm owned 2,840 shares of the company’s stock after selling 393 shares during the period. Guardian Wealth Advisors LLC’s holdings in Clorox were worth $418,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CLX. Norges Bank acquired a new position in shares of Clorox during the 4th quarter worth approximately $259,041,000. FMR LLC increased its position in shares of Clorox by 75.4% during the 4th quarter. FMR LLC now owns 1,361,758 shares of the company’s stock worth $221,163,000 after purchasing an additional 585,526 shares during the last quarter. KBC Group NV increased its position in shares of Clorox by 688.7% during the 1st quarter. KBC Group NV now owns 587,679 shares of the company’s stock worth $86,535,000 after purchasing an additional 513,171 shares during the last quarter. Marshall Wace LLP increased its position in shares of Clorox by 549.8% during the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company’s stock worth $88,144,000 after purchasing an additional 459,203 shares during the last quarter. Finally, ExodusPoint Capital Management LP increased its position in shares of Clorox by 187.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company’s stock worth $113,508,000 after purchasing an additional 456,114 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Analyst Ratings Changes

CLX has been the subject of several research analyst reports. Barclays set a $119.00 target price on Clorox and gave the stock an “underweight” rating in a research note on Tuesday. Citigroup reduced their target price on Clorox from $140.00 to $135.00 and set a “neutral” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. reduced their target price on Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research note on Tuesday, May 6th. UBS Group reduced their target price on Clorox from $176.00 to $154.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. Finally, Wells Fargo & Company reduced their target price on Clorox from $142.00 to $135.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $146.83.

Clorox Price Performance

Shares of NYSE CLX opened at $124.15 on Wednesday. The stock has a market capitalization of $15.30 billion, a PE ratio of 22.29, a P/E/G ratio of 3.14 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The business has a fifty day moving average price of $127.84 and a two-hundred day moving average price of $141.91. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. Clorox’s revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.71 earnings per share. As a group, equities analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction on Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director directly owned 4,000 shares of the company’s stock, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.